米非司酮治疗子宫切口瘢痕妊娠的效果分析  

Effectiveness of Mifepristone in the Management of Cesarean Scar Pregnancy

作　　者：陈明晖[1] 谢洪哲[1] 许玉芳 巫岳鹏[1] 

机构地区：[1]中山大学附属第一医院妇产科,广东省广州市510089 [2]广东省计划生育研究所

出　　处：《中国全科医学》2010年第12期1333-1334,共2页Chinese General Practice

摘　　要：目的探讨米非司酮在子宫切口瘢痕妊娠(CSP)治疗中的独立效果。方法回顾分析2003年1月—2009年12月我院确诊为CSP并接受米非司酮治疗的13例患者的病历资料,以治疗前后血绒毛膜促性腺激素(β-hCG)水平变化等分析米非司酮在CSP治疗中的独立作用。结果5例使用米非司酮作为负压吸引术后的后续治疗,血β-hCG均明显下降;6例使用米非司酮作为氨甲喋呤化疗后的后续治疗,2例患者血β-hCG明显下降;2例使用米非司酮作为初始治疗,1例患者血β-hCG明显下降。结论对接受负压吸引术后血β-hCG持续不下降的CSP患者,米非司酮作为后续治疗的效果明显;对接受氨甲喋呤治疗后血β-hCG下降不明显的CSP患者,米非司酮作为后续治疗效果多数不明显。Objective To evaluate the independent effectiveness of mifepristone in the management of cesarean scar pregnancy （CSP）.Methods The clinical data of 13 patients with CSP treated with mifepristone in our hospital from January 2003 to December 2009 were retrospectively analyzed.Change of serumβ-hCG level was used to estimate the independent role of mifepristone.Results Five patients were treated with mifepristone subsequently to suction curettage and the serum β-hCG of all these patients remarkably decreased.Six patients were treated with mifepristone subsequently to methotrexate;the serum β-hCG remarkably decrease in two of them.Two patients were treated with mifepristone initially and the serum β-hCG remarkably decreased in one patient.Conclusion Mifepristone is effective when applied as subsequent treatment in CSP patients whose β-hCG does not decrease after suction curettage treatment;however,its role may be limited when used as subsequent treatment following methotrexate.

关 键 词：米非司酮 妊娠 异位 绒毛膜促性腺激素 β亚单位 

分 类 号：R713.8[医药卫生—妇产科学]